ABSTRACT
About Muscle Relaxant Drugs
Muscle spasticity is caused by damage to the spinal cord or brain. Nerves in the brain and spinal cord help relax the muscles during the idle state. Conditions that affect the brain or spinal cord such as multiple sclerosis, cerebral palsy, and stroke can interfere with normal muscle relaxation, leading to involuntary muscle spasms. This will impair the ability to walk, work, sleep, or just function normally. The muscles can also become excessively tense and develop overactive or overresponsive reflexes. Severe cases can lead to deep disability, including an inability to straighten out joints.
Technavio’s analysts forecast the global muscle relaxant drugs market to grow at a CAGR of 5.64% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global muscle relaxant drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Muscle Relaxant Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Pfizer
• Ipsen Group
• Allergan
• Novartis
• Teva Pharmaceuticals
Other prominent vendors
• Acorda Therapeutics
• Aldeyra Therapeutics
• Canbex Therapeutics
• Daewoong
• Emcure Pharmaceuticals
• Endo International
• Fresenius Kabi
• Galderma
• INSYS Therapeutics
• Johnson & Johnson
• Lannett Company
• Merz Pharma
• Mylan
• Par Pharmaceutical
• PhytoTech Therapeutics
• Revance Therapeutics
• Sun Pharmaceutical Industries
• Takeda Pharmaceutical
Market driver
• Presence of a large patient pool driving adoption rates.
• For a full, detailed list, view our report
Market challenge
• Side effects associated with use of muscle relaxants hamper adoption rates.
• For a full, detailed list, view our report
Market trend
• Advanced drug delivery technologies fuels adoption of muscle relaxants.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: An overview of muscle spasticity and spasms
PART 06: Pipeline landscape
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by product category
• Skeletal muscle relaxant drugs
• Facial muscle relaxant drugs
PART 09: Geographical segmentation
• Muscle relaxant drugs market in Americas
• Muscle relaxant drugs market in EMEA
• Muscle relaxant drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments
PART 12: Market trends
• Anti-aging treatments driving adoption of facial relaxants
• Advanced drug delivery technologies fuels adoption of muscle relaxants
• Growing use of muscle relaxants in new indications and applications
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• Pfizer
• Allergan
• Ipsen Group
• Teva Pharmaceuticals
• Novartis
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Key muscle relaxants
Exhibit 02: Pipeline landscape
Exhibit 03: Global muscle relaxant drugs market snapshot
Exhibit 04: Global muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global muscle relaxant drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Global muscle relaxant drugs market by product category 2016
Exhibit 08: Global skeletal muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 09: Global facial muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 10: Global muscle relaxant drugs market by geography 2016 and 2021
Exhibit 11: Global muscle relaxant drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 12: Market scenario in Americas
Exhibit 13: Muscle relaxant drugs market in Americas 2016-2021 ($ millions)
Exhibit 14: Market scenario in EMEA
Exhibit 15: Muscle relaxant drugs market in EMEA 2016-2021 ($ millions)
Exhibit 16: Market scenario in APAC
Exhibit 17: Muscle relaxant drugs market in APAC 2016-2021 ($ millions)
Exhibit 18: Key approvals for new indications
Exhibit 19: Key factors driving the market growth
Exhibit 20: Impact of drivers
Exhibit 21: Impact of challenges
Exhibit 22: Competitive structure analysis of global muscle relaxant drugs market 2016
Exhibit 23: Competitive analysis of global muscle relaxant drugs market
Exhibit 24: Strategic success factors of companies in global muscle relaxant drugs market
Exhibit 25: Pfizer: Strength assessment
Exhibit 26: Pfizer: Strategy assessment
Exhibit 27: Pfizer: Opportunity assessment
Exhibit 28: Allergan: Key highlights
Exhibit 29: Allergan: Strength assessment
Exhibit 30: Allergan: Strategy assessment
Exhibit 31: Allergan: Opportunity assessment
Exhibit 32: Ipsen Group: Key highlights
Exhibit 33: Ipsen Group: Strength assessment
Exhibit 34: Ipsen Group: Strategy assessment
Exhibit 35: Ipsen Group: Opportunity assessment
Exhibit 36: Teva Pharmaceuticals: Strength assessment
Exhibit 37: Teva Pharmaceuticals: Strategy assessment
Exhibit 38: Teva Pharmaceuticals: Opportunity assessment
Exhibit 39: Novartis: Strength assessment
Exhibit 40: Novartis: Strategy assessment
Exhibit 41: Novartis: Opportunity assessment
